Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...

Investing.com -- The US Food and Drug Administration has accepted GlaxoSmithKline (NYSE: GSK )’s biologics license ...

Major pharmaceutical products and medicines have jumped in prices despite and executive order by President Bola Tinubu, ...

AI-powered tools like Merck’s Aiddison can accelerate drug identification and optimise design, cutting both costs and time to ...

The NCSD Speakers Bureau Roster features nearly 250 public speakers, celebrities, cancer survivors, and medical professionals eligible to ...

The demand for this year’s Oscars is an undeniable reflection of the show’s evergreen cultural influence, and a testament to ...

Pakistan Stock Exchange's (PSX) benchmark KSE-100 index experienced an extraordinary surge in 2024, recording an 85% increase ...

Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials ...

Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.